Targeting a specific protein to improve treatment response in brain cancer
Official title: Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity
Funded at University of Tennessee Health Sci Ctr · NIH-10886053 · Data updated 2026-11-12
This study is looking at ways to make treatments for glioblastoma, a tough type of brain cancer, work better by targeting a specific protein called BRG1, which helps the cancer resist treatment, so that patients can have a better chance at improved outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $482,829 |
| NIH project number | 5R01CA281977-02 |
| Project ID | NIH-10886053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are currently undergoing treatment or have treatment-resistant tumors.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain cancer that often resists treatment. The study aims to identify and target specific molecular pathways that contribute to the cancer's resistance, particularly focusing on a protein called BRG1. By using a small molecule inhibitor, the research seeks to enhance the effectiveness of existing therapies, such as DNA alkylating agents, and improve the immune response against the tumor. Patients may benefit from a more effective treatment strategy that could lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with glioblastoma, potentially increasing their survival rates.
How similar studies have gone: Previous research has shown promise in targeting similar molecular pathways in other cancers, suggesting potential for success in this approach for glioblastoma.
Where this research is happening
-
University of Tennessee Health Sci Ctr
Memphis, United States Active
Researchers
- Principal investigator: Pfeffer, Lawrence Marc — University of Tennessee Health Sci Ctr
- Study coordinator: Pfeffer, Lawrence Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.